Verdad Advisers’s Cullinan Therapeutics CGEM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-28,987
Closed -$528K – 210
2026
Q2
$528K Buy
28,987
+16,383
+130% +$243K 0.51% 74
2026
Q1
$179K Buy
+12,604
New +$162K 0.2% 137

Other funds holding CGEM

Verdad Advisers's CGEM Position: Q3 2026 in Review

Verdad Advisers sold out of Cullinan Therapeutics (CGEM) in Q3 2026, closing a stake of 28,987 shares — an estimated $528K sold.

Verdad Advisers first reported a position in CGEM in Q1 2026 and held it in 2 quarters. The position peaked at $528K in Q2 2026. 180 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Verdad Advisers reported no remaining Cullinan Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Verdad Advisers sold 28,987 Cullinan Therapeutics shares in Q3 2026, an estimated $528K.
  • Verdad Advisers first reported a position in Cullinan Therapeutics in Q1 2026 and held it in 2 quarters.
  • Verdad Advisers's Cullinan Therapeutics position peaked at $528K in Q2 2026.
  • 180 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.